IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.958
EU - Europa 3.251
AS - Asia 1.660
Continente sconosciuto - Info sul continente non disponibili 27
OC - Oceania 13
SA - Sud America 9
AF - Africa 4
Totale 26.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.938
CN - Cina 1.401
SE - Svezia 1.087
IT - Italia 569
UA - Ucraina 394
FI - Finlandia 348
GB - Regno Unito 281
DE - Germania 274
FR - Francia 105
VN - Vietnam 86
SG - Singapore 71
BE - Belgio 52
IN - India 45
IE - Irlanda 39
NL - Olanda 25
EU - Europa 24
IR - Iran 20
CA - Canada 15
CZ - Repubblica Ceca 14
ES - Italia 13
AU - Australia 10
GR - Grecia 8
HK - Hong Kong 8
RO - Romania 8
PT - Portogallo 6
RU - Federazione Russa 6
SA - Arabia Saudita 6
BG - Bulgaria 5
KR - Corea 5
IL - Israele 4
AR - Argentina 3
BD - Bangladesh 3
BR - Brasile 3
NZ - Nuova Zelanda 3
PL - Polonia 3
TR - Turchia 3
A1 - Anonimo 2
CH - Svizzera 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
JP - Giappone 2
MX - Messico 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
GL - Groenlandia 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
SY - Repubblica araba siriana 1
Totale 26.922
Salva come PNG Salva come JPEG
Città #
Fairfield 3.782
Woodbridge 2.606
Houston 1.761
Ashburn 1.721
Chandler 1.721
Seattle 1.491
Cambridge 1.275
Wilmington 1.173
Ann Arbor 1.080
Jacksonville 1.001
Nyköping 841
Lawrence 421
Roxbury 405
Nanjing 351
Des Moines 279
Beijing 271
Princeton 234
Bari 209
Boardman 207
New York 184
San Diego 165
Inglewood 142
Brooklyn 95
Dong Ket 85
Norwalk 85
Shenyang 84
Hebei 81
Nanchang 81
Dearborn 73
London 67
Tianjin 64
Jiaxing 63
Paris 59
Brussels 49
Guangzhou 47
Changsha 42
Singapore 42
Dublin 37
Los Angeles 36
Washington 32
Pune 30
Wuhan 27
Shanghai 26
Falls Church 23
Marseille 23
Mottola 22
Redwood City 19
Helsinki 18
Jinan 18
Kilburn 18
San Mateo 18
Taranto 18
Bisceglie 17
Leawood 17
Rome 16
Zhengzhou 16
Augusta 13
Hefei 13
Milan 13
Brno 12
Catania 12
Monmouth Junction 12
Munich 12
Auburn Hills 11
Chiswick 11
Indiana 11
Jinhua 10
San Francisco 10
Prescot 9
Ardabil 8
Hong Kong 8
Kunming 8
Toronto 8
Chicago 7
Edinburgh 7
Taizhou 7
Grafing 6
Hangzhou 6
Hounslow 6
Mumbai 6
Ningbo 6
Redmond 6
St Louis 6
Trani 6
Wuxi 6
Jeddah 5
Kansas City 5
Acton 4
Amsterdam 4
Bitonto 4
Cerignola 4
Dallas 4
Madrid 4
Melbourne 4
Mendicino 4
Seelze 4
St Albans 4
Stockholm 4
West Jordan 4
Yiwu 4
Totale 23.086
Salva come PNG Salva come JPEG
Nome #
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 159
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 157
Assessing response to interferon-β in a multicenter dataset of patients with MS 153
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 140
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 131
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 131
Prognostic indicators in pediatric clinically isolated syndrome 130
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 128
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 125
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 125
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 122
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 119
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 117
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 117
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 116
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 113
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 113
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 111
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 110
null 109
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 109
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 108
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 107
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 106
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 106
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 106
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 104
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 103
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 103
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 102
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 101
Age-related changes of serum N-acetyl-aspartate in healthy controls. 101
The role of sexual dysfunction and attachment style in migraine related quality of life 101
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 100
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 100
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 99
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 98
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study 98
Treating multiple sclerosis with natalizumab. 98
Comparative efficacy of switching to natalizumab in active multiple sclerosis 98
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 98
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. 97
Psychosocial issue in children and adolescents with multiple sclerosis 97
Multiple sclerosis registries in Europe – An updated mapping survey 97
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 96
A rare case of multiple sclerosis and McArdle disease 95
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 95
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 94
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies 94
Treatment decisions in multiple sclerosis-insights from real-world observational studies 94
Defining secondary progressive multiple sclerosis 94
Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 93
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. 93
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 93
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 93
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 93
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 92
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 92
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 92
Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis 91
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 91
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 91
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 91
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 90
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 90
null 90
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 89
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society 89
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 89
Can databasing optimise patient care? 88
Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation 88
Long term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 88
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 88
Natalizumab discontinuation and disease restart in pregnancy: A case series 88
The relationship between group A streptococcal infections and Tourette syndrome: a study on a large service-based cohort 87
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 87
The brief international cognitive assessment for multiple sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population 87
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 87
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study 86
Safety profile of Tysabri: international risk management plan 86
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 86
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration 86
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis 86
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 86
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study 86
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 86
Age-related disability in multiple sclerosis 86
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 85
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 85
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 85
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study 84
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study 84
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. 84
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 84
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 84
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 84
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis 84
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans 84
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study 83
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis 82
Totale 9.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.776 1.176 443 292 747 838 525 755 727 875 414 786 198
2020/20215.470 412 298 469 537 793 342 473 398 399 628 406 315
2021/20223.140 232 397 46 73 138 282 170 164 232 202 503 701
2022/20234.532 740 477 284 406 583 546 65 528 659 29 122 93
2023/20241.593 145 294 105 109 138 339 60 59 31 62 29 222
2024/2025210 210 0 0 0 0 0 0 0 0 0 0 0
Totale 28.289